Strides Pharma Science Limited (Strides or Company), a global pharmaceutical company today announced that it has developed and commercialized Favipiravir Antiviral tablets. The product is a generic version of Avigan® of Toyama Chemical, Japan. Favipiravir is an antiviral medication that was initially developed to treat influenza in Japan.

Cipla has applied for permission from DCGI to market Favipiravir in India as an experimental medicine for COVID-19. Under the guidances of ICMR, Cipla will also conduct a suitable limited trial prior to marketing the product as Ciplenza.










